TAILOR试验:新诊断精神分裂症或持续性妄想障碍患者精神病性症状缓解后抗精神病药物逐渐减停与维持治疗的随机临床试验方案
TAILOR试验旨在比较密切监测下逐渐减停与维持抗精神病药物治疗对新诊断精神分裂症或持续性妄想障碍且精神病性症状缓解至少3个月患者的效果。将从丹麦两个地区OPUS早期干预项目纳入250例患者,随机接受1年维持治疗或逐渐减停(减停组使用智能手机应用监测复发早期预警信号)。主要结局为1年后精神病性症状缓解且未使用抗精神病药物。
要点
- 纳入标准为ICD-10精神分裂症(F20,除外F20.6)或持续性妄想障碍(F22),精神病性症状缓解至少3个月且正在接受抗精神病药物(除外氯氮平)治疗。
- 250例患者随机分为维持治疗组或逐渐减停组,干预1年,减停组使用智能手机应用监测精神病性复发早期预警信号。
- 主要结局为1年后精神病性症状缓解且未使用抗精神病药物,随访至5年。
核心结论
- TAILOR试验将提供关于精神分裂症及相关障碍早期阶段逐渐减停抗精神病药物效果的知识,结果可能指导未来抗精神病药物治疗的临床方案。
研究设计与样本
- 随机临床试验方案,计划从丹麦两个地区精神科早期干预项目OPUS纳入250例患者。
- 纳入标准为ICD-10精神分裂症(F20,除外F20.6)或持续性妄想障碍(F22),精神病性症状缓解至少3个月,正在接受抗精神病药物(除外氯氮平)治疗。
- 患者随机分为维持治疗组或逐渐减停组,干预1年;减停组使用智能手机应用监测精神病性复发早期预警信号。
- 在基线、1年、2年和5年随访时评估精神病性和阴性症状、抗精神病药物副作用、社会功能、认知功能、感知健康状况、患者满意度、物质和酒精使用、性功能和生活质量。
关键数值与推荐
- 主要结局为1年后精神病性症状缓解且未使用抗精神病药物。
- 次要结局包括:1年干预后精神病性症状缓解且抗精神病药物剂量为0-1 mg氟哌啶醇当量;抗精神病药物剂量;抗精神病药物副作用;阴性症状;社会功能;认知功能;患者满意度。
- 探索性结局包括缓解、临床康复、物质和酒精使用、性功能、生活质量、应对自我信念以及患者对卫生工作者支持的体验。
- 安全性指标包括死亡、精神科住院、严重自伤和精神病性复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of the TAILOR trial is to investigate the effect of closely monitored tapering/discontinuation versus maintenance therapy with antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder and with minimum 3 months' remission of psychotic symptoms. METHODS AND DESIGN: Two hundred and fifty patients will be included from the psychiatric early intervention program, OPUS, in two regions in Denmark. Inclusion criteria are: ICD-10 diagnoses schizophrenia (F20, except F20.6) or persistent delusional disorder (F22), minimum 3 months' remission of psychotic symptoms and in treatment with antipsychotic medication (except clozapine). The patients will be randomized to maintenance therapy or tapering/discontinuation with antipsychotic medication in a 1-year intervention. The tapering/discontinuation group will be using a smartphone application to monitor early warning signs of psychotic relapse. Patients will be assessed at baseline, 1-, 2- and 5-year follow-up regarding psychotic and negative symptoms, side-effects of antipsychotic medication, social functioning, cognitive functioning, perceived health status, patient satisfaction, substance and alcohol use, sexual functioning and quality of life. The primary outcome will be remission of psychotic symptoms and no antipsychotic medication after 1 year. Secondary outcome measures will include: co-occurrence of remission of psychotic symptoms and 0-1-mg haloperidol equivalents of antipsychotic medication after 1-year intervention; antipsychotic dose; antipsychotic side effects; negative symptoms; social functioning; cognitive functioning; and patient satisfaction. Exploratory outcomes will include remission, clinical recovery, substance and alcohol use, sexual functioning, quality of life, self-beliefs of coping and user experience of support from health workers. Safety measures will include death, admissions to psychiatric hospital, severe self-harm and psychotic relapses. DISCUSSION: The TAILOR trial will contribute knowledge about the effect of tapering/discontinuation of antipsychotic medication in the early phases of schizophrenia and related disorders and the results may guide future clinical treatment regimens of antipsychotic treatment. TRIAL REGISTRATION: EU Clinical Trials Register - EudraCT number: 2016-000565-23 . Registered on 5 February 2016.
引用
- Stürup AE, Jensen HD, Dolmer S, et al. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. Trials. 2017. PMID: 28962668. doi:10.1186/s13063-017-2172-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。